1 INTRODUCTION

1.1 MARKET DEFINITION

1.2 MARKET SEGMENTATION

1.3 RESEARCH TIMELINES

1.4 ASSUMPTIONS

1.5 LIMITATIONS
2 RESEARCH METHODOLOGY

2.1 DATA MINING

2.2 SECONDARY RESEARCH

2.3 PRIMARY RESEARCH

2.4 SUBJECT MATTER EXPERT ADVICE

2.5 QUALITY CHECK

2.6 FINAL REVIEW

2.7 DATA TRIANGULATION

2.8 BOTTOM-UP APPROACH

2.9 TOP-DOWN APPROACH

2.10 RESEARCH FLOW
3 EXECUTIVE SUMMARY

3.1 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET OVERVIEW

3.2 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ESTIMATES AND FORECAST (USD MILLION), 2022-2031

3.3 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ECOLOGY MAPPING (% SHARE IN 2023)

3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM

3.5 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ABSOLUTE MARKET OPPORTUNITY

3.6 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ATTRACTIVENESS ANALYSIS, BY REGION

3.7 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ATTRACTIVENESS ANALYSIS, BY END USER

3.8 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION

3.9 CELL & GENE THERAPY DEVELOPMENT ATTRACTIVENESS ANALYSIS, BY THERAPY TYPES

3.10 CELL & GENE THERAPY DEVELOPMENT ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY

3.11 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET GEOGRAPHICAL ANALYSIS (CAGR %)

3.12 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY END USER (USD MILLION)

3.13 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY APPLICATION (USD MILLION)

3.14 CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY (USD MILLION)

3.15 CELL & GENE THERAPY DEVELOPMENT, BY THERAPY TYPES (USD MILLION)

3.16 FUTURE MARKET OPPORTUNITIES
4 MARKET OUTLOOK
4.1 U.S. & EUROPE GENETIC INTEGRITY TESTING MARKET EVOLUTION
4.2 U.S. & EUROPE GENETIC INTEGRITY TESTING MARKET OUTLOOK
4.3 MARKET DRIVERS

4.3.1 GROWING PREVALENCE OF GENETIC DISEASES

4.3.2 GROWING DEMAND OF PERSONALIZED MEDICINE
4.4 MARKET RESTRAINTS

4.4.1 HIGH COST OF GENETIC TESTING
4.5 MARKET TRENDS

4.5.1 GROWING ADOPTION OF GENETIC INTEGRITY TESTING IN SINGLE CELL ANALYSIS

4.5.2 NEW TREND OF LIQUID BIOPSY FOR CANCER MONITORING
4.6 MARKET OPPORTUNITY

4.6.1 GROWING NEUROLOGICAL DISORDERS AIDING THE NEURO-RESEARCH

4.6.2 NEW OPPORTUNITIES FROM GROWING DEMAND FROM ACADEMIA SEGMENT
4.7 PORTER’S FIVE FORCES ANALYSIS

4.7.1 THREAT OF NEW ENTRANTS: LOW TO MODERATE

4.7.2 THREAT OF SUBSTITUTES: LOW

4.7.3 BARGAINING POWER OF SUPPLIERS: LOW TO MODERATE

4.7.4 BARGAINING POWER OF BUYERS: MODERATE

4.7.5 INTENSITY OF COMPETITIVE RIVALRY: HIGH
4.8 MACROECONOMIC ANALYSIS
4.9 PRODUCT LIFELINE
4.10 METHODOLOGIES FOR GENOME EDITING AND CANCER APPLICATION

4.10.1 CRISPR-CAS9

4.10.1.1 CRISPR-CAS9

4.10.1.2 PROS

4.10.1.3 CANCER APPLICATIONS

4.10.1.4 LIMITATIONS OF CRISPR-CAS9

4.10.2 TALENS (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES)

4.10.2.1 TALENS (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES)

4.10.2.2 PROS

4.10.2.3 CANCER APPLICATIONS

4.10.2.4 LIMITATIONS OF TALENS

4.10.3 ZFNS (ZINC FINGER NUCLEASES)

4.10.3.1 ZFNS (ZINC FINGER NUCLEASES)

4.10.3.2 PROS

4.10.3.3 CANCER APPLICATIONS

4.10.3.4 LIMITATIONS OF ZFNS (ZINC FINGER NUCLEASES)

4.10.4 HOMING ENDONUCLEASES OR MEGANUCLEASES

4.10.4.1 HOMING ENDONUCLEASES OR MEGANUCLEASES

4.10.4.2 PROS

4.10.4.3 CANCER APPLICATIONS

4.10.4.4 LIMITATIONS OF HOMING ENDONUCLEASES OR MEGANUCLEASES
5 MARKET, BY APPLICATION

5.1 OVERVIEW

5.2 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION

5.1 CELL & GENE THERAPY DEVELOPMENT

5.2 CANCER RESEARCH

5.3 CELL LINE & CELL BANK CHARACTERIZATION
6 MARKET, BY END-USER

6.1 OVERVIEW

6.2 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END-USER

6.3 PHARMA

6.4 ACADEMIA
7 MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY

7.1 OVERVIEW

7.2 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY

7.3 G-BANDING

7.4 CHROMOSOMAL MICROARRAY (CMA)

7.5 FLUORESCENCE IN SITU HYBRIDIZATION (FISH):

7.6 OPTICAL GENOME IMAGING

7.7 WHOLE GENOME SEQUENCING (WGS)

7.8 OTHERS
8 MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY THERAPY TYPES

8.1 OVERVIEW

8.2 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY CELL & GENE THERAPY DEVELOPMENT, BY THERAPY TYPES

8.1 GENOME-EDITED CELLS

8.2 UNEDITED STEM CELLS
9 MARKET, BY GEOGRAPHY

9.1 OVERVIEW

9.1.1 THE U.S AND EUROPE MARKET SNAPSHOT

9.2 THE U.S.

9.3 EUROPE

9.3.1 EUROPE MARKET SNAPSHOT

9.3.2 GERMANY

9.3.3 U.K.

9.3.4 FRANCE

9.3.5 ITALY

9.3.6 SPAIN

9.3.7 REST OF EUROPE
10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE SCENARIO

10.3 COMPANY MARKET RANKING ANALYSIS

10.4 COMPANY REGIONAL FOOTPRINT

10.5 COMPANY INDUSTRY FOOTPRINT

10.6 ACE MATRIX

10.6.1 ACTIVE

10.6.2 CUTTING EDGE

10.6.3 EMERGING

10.6.4 INNOVATORS
11 COMPANY PROFILES
11.1 THERMO FISHER SCIENTIFIC

11.1.1 COMPANY OVERVIEW

11.1.2 COMPANY INSIGHTS

11.1.3 SEGMENT INSIGHTS

11.1.4 PRODUCT BENCHMARKING

11.1.5 SWOT ANALYSIS

11.1.6 WINNING IMPERATIVES

11.1.7 CURRENT FOCUS & STRATEGIES

11.1.8 THREAT FROM COMPETITION
11.2 DANAHER

11.2.1 COMPANY OVERVIEW

11.2.2 COMPANY INSIGHTS

11.2.3 SEGMENT INSIGHTS

11.2.4 PRODUCT BENCHMARKING

11.2.5 KEY DEVELOPMENT

11.2.6 SWOT ANALYSIS

11.2.7 WINNING IMPERATIVES

11.2.8 CURRENT FOCUS & STRATEGIES

11.2.9 THREAT FROM COMPETITION
11.3 MERCK.

11.3.1 COMPANY OVERVIEW

11.3.2 COMPANY INSIGHTS

11.3.3 SEGMENT INSIGHTS

11.3.4 PRODUCT BENCHMARKING

11.3.5 SWOT ANALYSIS

11.3.6 WINNING IMPERATIVES

11.3.7 CURRENT FOCUS & STRATEGIES

11.3.8 THREAT FROM COMPETITION
11.4 WUXI ADVANCED THERAPIES

11.4.1 COMPANY OVERVIEW

11.4.2 COMPANY INSIGHTS

11.4.3 SEGMENT BREAKDOWN

11.4.4 PRODUCT BENCHMARKING

11.4.5 SWOT ANALYSIS

11.4.6 WINNING IMPERATIVES

11.4.7 CURRENT FOCUS & STRATEGIES

11.4.8 THREAT FROM COMPETITION
11.5 CHARLES RIVER

11.5.1 COMPANY OVERVIEW

11.5.2 COMPANY INSIGHTS

11.5.3 SEGMENT BREAKDOWN

11.5.4 PRODUCT BENCHMARKING

11.5.5 KEY DEVELOPMENTS

11.5.6 SWOT ANALYSIS

11.5.7 WINNING IMPERATIVES

11.5.8 CURRENT FOCUS & STRATEGIES

11.5.9 THREAT FROM COMPETITION
11.6 AVANCE BIOSCIENCES.

11.6.1 COMPANY OVERVIEW

11.6.2 COMPANY INSIGHTS

11.6.3 PRODUCT BENCHMARKING
11.7 MOLECULAR DIAGNOSTIC SERVICES INC. (MDS)

11.7.1 COMPANY OVERVIEW

11.7.2 COMPANY INSIGHTS

11.7.3 PRODUCT BENCHMARKING
11.8 VIRUSURE

11.8.1 COMPANY OVERVIEW

11.8.2 COMPANY INSIGHTS

11.8.3 SEGMENT BREAKDOWN

11.8.4 PRODUCT BENCHMARKING
11.9 EUROFINS BIOPHARMA PRODUCT TESTING

11.9.1 COMPANY OVERVIEW

11.9.2 COMPANY INSIGHTS

11.9.3 PRODUCT BENCHMARKING

11.9.4 KEY DEVELOPMENTS
11.10 CREATIVE BIOLABS

11.10.1 COMPANY OVERVIEW

11.10.2 COMPANY INSIGHTS

11.10.3 PRODUCT BENCHMARKING
11.11 SARTORIUS

11.11.1 COMPANY OVERVIEW

11.11.2 COMPANY INSIGHTS

11.11.3 SEGMENT BREAKDOWN

11.11.4 PRODUCT BENCHMARKING

11.11.5 KEY DEVELOPMENTS
11.12 CD BIOSCIENCES

11.12.1 COMPANY OVERVIEW

11.12.2 COMPANY INSIGHTS

11.12.3 PRODUCT BENCHMARKING
LIST OF TABLES
TABLE 1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES

TABLE 2 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 3 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 4 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 5 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY THERAPY TYPES, 2022-2031 (USD MILLION)

TABLE 6 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY GEOGRAPHY, 2022-2031 (USD MILLION)

TABLE 7 THE U.S. GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 8 THE U.S. GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 9 THE U.S. GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 10 THE U.S. GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 11 EUROPE GENETIC INTEGRITY TESTING MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 12 EUROPE GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 13 EUROPE GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 14 EUROPE GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 15 EUROPE GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 16 GERMANY GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 17 GERMANY GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 18 GERMANY GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 19 GERMANY GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 20 U.K GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 21 U.K GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 22 U.K GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 23 U.K GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 24 FRANCE GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 25 FRANCE GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 26 FRANCE GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 27 FRANCE GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 28 ITALY GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 29 ITALY GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 30 ITALY GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 31 ITALY GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 32 SPAIN GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 33 SPAIN GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 34 SPAIN GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 35 SPAIN GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 36 REST OF EUROPE GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 37 REST OF EUROPE GENETIC INTEGRITY TESTING MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 38 REST OF EUROPE GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 39 REST OF EUROPE GENETIC INTEGRITY TESTING MARKET, BY END-USER, 2022-2031 (USD MILLION)

TABLE 40 COMPANY REGIONAL FOOTPRINT

TABLE 41 COMPANY INDUSTRY FOOTPRINT

TABLE 42 THERMO FISHER SCIENTIFIC: PRODUCT BENCHMARKING

TABLE 43 THERMO FISHER SCIENTIFIC: WINNING IMPERATIVES

TABLE 44 DANAHER: PRODUCT BENCHMARKING

TABLE 45 DANAHER: KEY DEVELOPMENT

TABLE 46 DANAHER: WINNING IMPERATIVES

TABLE 47 MERCK.: PRODUCT BENCHMARKING

TABLE 48 MERCK: WINNING IMPERATIVES

TABLE 49 WUXI ADVANCED THERAPIES: PRODUCT BENCHMARKING

TABLE 50 WUXI ADVANCED THERAPIES: WINNING IMPERATIVES

TABLE 51 CHARLES RIVER: PRODUCT BENCHMARKING

TABLE 52 CHARLES RIVER: KEY DEVELOPMENTS

TABLE 53 CHARLES RIVER: WINNING IMPERATIVES

TABLE 54 AVANCE BIOSCIENCES.: PRODUCT BENCHMARKING

TABLE 55 MOLECULAR DIAGNOSTIC SERVICES INC. (MDS): PRODUCT BENCHMARKING

TABLE 56 VIRUSURE: PRODUCT BENCHMARKING

TABLE 57 EUROFINS BIOPHARMA PRODUCT TESTING: PRODUCT BENCHMARKING

TABLE 58 EUROFINS BIOPHARMA PRODUCT TESTING: KEY DEVELOPMENTS

TABLE 59 CREATIVE BIOLABS: PRODUCT BENCHMARKING

TABLE 60 SARTORIUS: PRODUCT BENCHMARKING

TABLE 61 SARTORIUS: KEY DEVELOPMENTS

TABLE 62 CD BIOSCIENCES: PRODUCT BENCHMARKING
LIST OF FIGURES
FIGURE 1 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET SEGMENTATION

FIGURE 2 RESEARCH TIMELINES

FIGURE 3 DATA TRIANGULATION

FIGURE 4 MARKET RESEARCH FLOW

FIGURE 5 SUMMARY

FIGURE 6 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ESTIMATES AND FORECAST (USD MILLION), 2022-2031

FIGURE 7 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ECOLOGY MAPPING (% SHARE IN 2023)

FIGURE 8 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM

FIGURE 9 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ABSOLUTE MARKET OPPORTUNITY

FIGURE 10 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ATTRACTIVENESS ANALYSIS, BY REGION

FIGURE 11 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ATTRACTIVENESS ANALYSIS, BY END USER

FIGURE 12 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION

FIGURE 13 CELL & GENE THERAPY DEVELOPMENT ATTRACTIVENESS ANALYSIS, BY THERAPY TYPES

FIGURE 14 CELL & GENE THERAPY DEVELOPMENT ATTRACTIVENESS ANALYSIS, BY TECHNOLOGY

FIGURE 15 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET GEOGRAPHICAL ANALYSIS, 2024-3031

FIGURE 16 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY END USER (USD MILLION)

FIGURE 17 THE U.S AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY APPLICATION (USD MILLION)

FIGURE 18 CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY (USD MILLION)

FIGURE 19 CELL & GENE THERAPY DEVELOPMENT, BY THERAPY TYPES (USD MILLION)

FIGURE 20 FUTURE MARKET OPPORTUNITIES

FIGURE 21 U.S. & EUROPE GENETIC INTEGRITY TESTING MARKET OUTLOOK

FIGURE 22 MARKET DRIVERS_IMPACT ANALYSIS

FIGURE 23 NUMBER OF NEW CANCER CASES IN U.S. (2023)

FIGURE 24 RESTRAINTS_IMPACT ANALYSIS

FIGURE 25 THYROID CANCER DIAGNOSTIC ALGORITHMIC TESTS (PRICE PER TEST IN USD)

FIGURE 26 KEY TRENDS

FIGURE 27 MARKET OPPORTUNITY_IMPACT ANALYSIS

FIGURE 28 GROWING DEMAND FROM ACADEMIA: 2022-2031

FIGURE 29 PORTER’S FIVE FORCES ANALYSIS

FIGURE 30 PRODUCT LIFELINE: GENETIC INTEGRITY TESTING MARKET

FIGURE 31 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY APPLICATION

FIGURE 32 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION

FIGURE 33 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY END-USER

FIGURE 34 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY END-USER

FIGURE 35 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY

FIGURE 36 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY CELL & GENE THERAPY DEVELOPMENT, BY TECHNOLOGY

FIGURE 37 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY CELL & GENE THERAPY DEVELOPMENT, BY THERAPY

FIGURE 38 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET BASIS POINT SHARE (BPS) ANALYSIS, BY CELL & GENE THERAPY DEVELOPMENT, BY THERAPY TYPES

FIGURE 39 THE U.S. AND EUROPE GENETIC INTEGRITY TESTING MARKET, BY GEOGRAPHY, 2022-2031 (USD MILLION)

FIGURE 40 THE U.S. MARKET SNAPSHOT

FIGURE 41 GERMANY MARKET SNAPSHOT

FIGURE 42 U.K. MARKET SNAPSHOT

FIGURE 43 FRANCE MARKET SNAPSHOT

FIGURE 44 ITALY MARKET SNAPSHOT

FIGURE 45 SPAIN MARKET SNAPSHOT

FIGURE 46 REST OF EUROPE MARKET SNAPSHOT

FIGURE 47 KEY STRATEGIC DEVELOPMENTS

FIGURE 48 COMPANY MARKET RANKING ANALYSIS

FIGURE 49 ACE MATRIC

FIGURE 50 THERMO FISHER SCIENTIFIC: COMPANY INSIGHT

FIGURE 51 THERMO FISHER SCIENTIFIC: COMPANY INSIGHT

FIGURE 52 THERMO FISHER SCIENTIFIC INC: SWOT ANALYSIS

FIGURE 53 DANAHER: COMPANY INSIGHT

FIGURE 54 DANAHER: COMPANY INSIGHT

FIGURE 55 DANAHER: SWOT ANALYSIS

FIGURE 56 MERCK.: COMPANY INSIGHT

FIGURE 57 MERCK: COMPANY INSIGHT

FIGURE 58 MERCK: SWOT ANALYSIS

FIGURE 59 WUXI ADVANCED THERAPIES: COMPANY INSIGHT

FIGURE 60 WUXI ADVANCED THERAPIES: BREAKDOWN

FIGURE 61 WUXI ADVANCED THERAPIES: SWOT ANALYSIS

FIGURE 62 CHARLES RIVER: COMPANY INSIGHT

FIGURE 63 CHARLES RIVER: BREAKDOWN

FIGURE 64 CHARLES RIVER: SWOT ANALYSIS

FIGURE 65 AVANCE BIOSCIENCES.: COMPANY INSIGHT

FIGURE 66 MOLECULAR DIAGNOSTIC SERVICES INC. (MDS): COMPANY INSIGHT

FIGURE 67 VIRUSURE: COMPANY INSIGHT

FIGURE 68 VIRUSURE: BREAKDOWN

FIGURE 69 EUROFINS BIOPHARMA PRODUCT TESTING: COMPANY INSIGHT

FIGURE 70 CREATIVE BIOLABS: COMPANY INSIGHT

FIGURE 71 SARTORIUS: COMPANY INSIGHT

FIGURE 72 SARTORIUS: BREAKDOWN

FIGURE 73 CD BIOSCIENCES: COMPANY INSIGHT

The research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistics agencies, and paid databases. This information creates a base for the study. The information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points which currently affect or are likely to affect the industry during the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation and forecast, which generates the quantitative figures of the market/sub-segments in the current scenario as well as for the forecast period. 

After estimating the markets and estimates, the numbers are verified with industry participants and key opinion leaders. The wide network of industry participants add value to the research and verify the numbers and estimates provided in the study. At the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The below figure contains the different stages of the research process to produce the report.

1.1 DATA MINING
Data mining is an extensive part of our research process. It involves the procurement of market data and related information from different verified and credible sources. This step helps to obtain raw information about the industry and their Drivetrain, the monetary process for different end uses, the pool of market participants, and the nature of the industry and scope of the study. The data mining stage comprises both primary and secondary sources of information.
1.2 SECONDARY RESEARCH
In the secondary research process, various sources are used to identify and gather industry trends and information for the research process. We at TRI have access to some of the most diversified and extensive paid databases, which give us the most accurate data/information on markets Customers, and pricing. Mentioned below is a detailed list of sources that have been used for this study. Please note that this list is not limited to the names as mentioned; we also access other data sources depending on the need.
1.3 PRIMARY RESEARCH
In the primary research process, in-depth primary interviews are conducted with the CXOs to understand the market share, customer base, pricing strategies, channel partners, and other necessary information. Besides, in-depth primary interviews are conducted with the CXOs of vendors, channel partners, and others to validate the supply-side information. In addition, various key industry participants from both the supply and demand side are interviewed to obtain qualitative and quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (Corporates), industry consultants, and C-Component executives of major companies, are conducted to obtain critical qualitative and quantitative information pertaining to the market, as well as to assess the prospects for market growth during the forecast period. Detailed information on these primary respondents is mentioned below. 
1.4 FORCASTING TECHNIQUES
We at Markstats Research Insights Private Limited follow an extensive process for arriving at market estimations, which involves the use of multiple forecasting techniques as mentioned below.